{"transactions":[{"id":743430,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:34:13.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":19475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1. The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":19475,"derivative":{"exercise_price":20.56,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":19475},"source":{"system":"sec-edgar","filing":"0001628280-26-042251","document":"wk-form4_1781123650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000162828026042251/wk-form4_1781123650.xml","form_type":"4"}},{"id":1116633,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T20:31:38.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":23746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":23746,"derivative":{"exercise_price":11.48,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":23746},"source":{"system":"sec-edgar","filing":"0002023658-25-000078","document":"wk-form4_1749587491.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000202365825000078/wk-form4_1749587491.xml","form_type":"4"}},{"id":1406875,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Redeemable Convertible Preferred Stock","published_at":"2024-09-16T20:35:31.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":4000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Carica Investments"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Carica Investments (\"Carica\"). The Reporting Person is the managing partner of Carica and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":432736},"source":{"system":"sec-edgar","filing":"0000950170-24-106866","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000095017024106866/ownership.xml","form_type":"4"}},{"id":1406874,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Redeemable Convertible Preferred Stock","published_at":"2024-09-16T20:35:31.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":3000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Glentech International"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Glentech International (\"Glentech\"). The Reporting Person is the managing member of Glentech and disclaims beneficial ownership of such shares for purposes of Section 16 of Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":324552},"source":{"system":"sec-edgar","filing":"0000950170-24-106866","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000095017024106866/ownership.xml","form_type":"4"}},{"id":1406873,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Redeemable Convertible Preferred Stock","published_at":"2024-09-16T20:35:31.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":9990144,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Biocon Pharma Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Biocon Pharma Inc. (\"Biocon Pharma\"). The Reporting Person is the managing member of Biocon Pharma and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1080775},"source":{"system":"sec-edgar","filing":"0000950170-24-106866","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000095017024106866/ownership.xml","form_type":"4"}},{"id":1406872,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Redeemable Convertible Preferred Stock","published_at":"2024-09-16T20:35:31.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":40000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Biocon Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Biocon Limited (\"Biocon Ltd\"). The Reporting Person is the managing member of Biocon Ltd and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4327365},"source":{"system":"sec-edgar","filing":"0000950170-24-106866","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000095017024106866/ownership.xml","form_type":"4"}},{"id":1406871,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-16T20:35:31.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":23746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":23746,"derivative":{"exercise_price":18,"expiration_date":"2034-09-12","underlying":"Common Stock","underlying_shares":23746},"source":{"system":"sec-edgar","filing":"0000950170-24-106866","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000095017024106866/ownership.xml","form_type":"4"}},{"id":1406870,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T20:35:31.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":432736,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Carica Investments"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Carica Investments (\"Carica\"). The Reporting Person is the managing partner of Carica and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":432736,"source":{"system":"sec-edgar","filing":"0000950170-24-106866","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000095017024106866/ownership.xml","form_type":"4"}},{"id":1406869,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T20:35:31.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":324552,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Glentech International"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Glentech International (\"Glentech\"). The Reporting Person is the managing member of Glentech and disclaims beneficial ownership of such shares for purposes of Section 16 of Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":324552,"source":{"system":"sec-edgar","filing":"0000950170-24-106866","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000095017024106866/ownership.xml","form_type":"4"}},{"id":1406868,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T20:35:31.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":1080775,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Biocon Pharma Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Biocon Pharma Inc. (\"Biocon Pharma\"). The Reporting Person is the managing member of Biocon Pharma and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1080775,"source":{"system":"sec-edgar","filing":"0000950170-24-106866","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000095017024106866/ownership.xml","form_type":"4"}},{"id":1406867,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39735,"kind":"person","name":"Mazumdar-Shaw Kiran","position":1,"cik":"0002034672","reported_name":"Mazumdar-Shaw Kiran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T20:35:31.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":4327365,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Biocon Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Biocon Limited (\"Biocon Ltd\"). The Reporting Person is the managing member of Biocon Ltd and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4443122,"source":{"system":"sec-edgar","filing":"0000950170-24-106866","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034672/000095017024106866/ownership.xml","form_type":"4"}}]}